STEPHANOS KYRKANIDES, D.D.S.
Dentist in Stonybrook, NY
License number
New York 049434
Category
Dentist
Type
Orthodontics and Dentofacial Orthopedics
Address
Address
114 Rockland Hall Stony Brk, Stonybrook, NY 11794
Phone
(585) 472-6451
(631) 632-8717 (Fax)
(631) 632-8717 (Fax)
Professional information
Dr. Stephanos Kyrkanides, Stony Brook NY - DDS (Doctor of Dental Surgery)
Specialties:
Orthodontics, Orthodontics & Dentofacial Orthopedics
Address:
114 Rockland Hall, Stony Brook 11794
(631) 632-8717 (Fax)
(631) 632-8717 (Fax)
Languages:
English
Compositions Targeting The Soluble Extracellular Domain Of E-Cadherin And Related Methods For Cancer Therapy
US Patent:
2013028, Oct 31, 2013
Filed:
Oct 27, 2011
Appl. No.:
13/882078
Inventors:
Sabine Brouxhon - Stony Brook NY, US
M. Kerry O'Banion - Pittsford NY, US
Stephanos Kyrkanides - Stony Brook NY, US
M. Kerry O'Banion - Pittsford NY, US
Stephanos Kyrkanides - Stony Brook NY, US
Assignee:
The Research Foundation of State University of New York - Albany NY
International Classification:
A61K 39/395, A61K 39/00, G01N 33/50, C07K 14/47, C07K 16/18, A61K 45/00, G01N 33/574
US Classification:
4241391, 514 44 R, 4241851, 4241781, 435 792, 530395, 5303879, 4353201, 435 71
Abstract:
The present invention is based, in part, on our discovery that targeting epitopes within one or more of the EC2-EC5 subdomains of E-cadherin results in the death of epithelial-derived tumor cells but not in the death of normal, healthy epithelial cells or non-epithelial cells including endothelial cells and fibroblasts. Accordingly, the compositions of the invention include poly-peptides having an amino acid sequence of one or more of the EC2-EC5 subdomains of E-cadherin and biologically active variants thereof; expression vectors and cells for expressing such polypeptides; and agents (e.g., antibodies) that target the EC2-EC5 subdomains. The methods of the invention include methods of identifying and producing polypeptides having an amino acid sequence of one or more of the EC2-EC5 subdomains of E-cadherin or a biologically active variant thereof; methods of generating agents, such as antibodies, that target these polypeptides; and methods of administering such agents or eliciting their production in vivo to treat epithelial cancers or reduce the risk of their occurrence or recurrence.